Specifically, its association with EZH2, the catalytic subunit of the PRC2 complex, has been demonstrated in cancers such as pancreatic cancer (Cheng et al., 2018) and castration-resistant prostate cancer (Wang et al., 2015). The gene discussed is EZH2; the disease is cancer.